```html

Jervell & Lange‑Nielsen Syndrome (Long QT Type 1)

Overview

Jervell and Lange‑Nielsen syndrome (JLNS) is a rare, inherited disorder that combines two major problems:

• Congenital long QT interval on the electrocardiogram (ECG), which predisposes the heart to dangerous ventricular arrhythmias.
• Congenital sensorineural hearing loss that is usually present from birth.

JLNS is classified as **long QT type 1 (LQT1)** because most affected individuals have mutations in the KCNQ1 gene, the same gene that causes the more common, isolated LQT1. When the same mutation occurs together with bilateral hearing loss, the condition meets the clinical definition of JLNS.

Who it affects: The disease is autosomal‑recessive, meaning a child must inherit a defective copy of the gene from each parent. Both males and females are equally affected.

Prevalence: JLNS is extremely rare—estimated at **1 in 250,000 to 1 in 500,000 live births** worldwide [1, 2]. By contrast, isolated congenital LQT1 occurs in roughly 1 in 5,000 people.

Because of its rarity, many physicians are unfamiliar with JLNS, making early recognition crucial for preventing sudden cardiac death.

Symptoms

The clinical picture consists of cardiac and auditory findings. Symptoms can appear in the newborn period, early childhood, or even later in adolescence.

Cardiac symptoms

• Syncope (fainting) – often triggered by sudden noises, exercise, or emotional stress.
• Palpitations – sensation of rapid or irregular heartbeats.
• Seizure‑like activity – sometimes mistaken for epilepsy when a brief arrhythmic episode leads to cerebral hypoxia.
• Sudden cardiac arrest (SCA) – can be the first manifestation; the most feared outcome.
• Cardiac arrest during sleep – especially in infants; may present as “infant death” without warning.

Auditory symptoms

• Congenital sensorineural hearing loss – typically bilateral, moderate‑to‑severe, present at birth.
• Delayed speech and language development – secondary to hearing impairment.
• Family history of deafness – often suggests an autosomal‑recessive inheritance pattern.

Other possible findings

• Developmental delay (related to hearing loss rather than the heart condition).
• Fatigue or exercise intolerance due to episodes of arrhythmia.

Causes and Risk Factors

JLNS is caused by pathogenic variants in genes that encode proteins essential for potassium flow in cardiac cells and inner‑ear hair cells.

Genetic cause

• KCNQ1 mutations – the most common; the gene encodes the Kv7.1 potassium channel. Loss‑of‑function mutations prolong the cardiac action potential, lengthening the QT interval.
• KCNJ5 mutations – less common; affect the Kir3.4 channel.
• Both genes are also expressed in the stria vascularis of the cochlea, explaining the associated hearing loss.

Inheritance pattern

• Autosomal‑recessive: each parent carries one defective allele (often asymptomatic carriers) and has a 25 % chance of having an affected child.
• Consanguinity (marriage between relatives) increases the likelihood of homozygous mutations.

Risk factors

• Family history of JLNS, unexplained sudden death, or congenital deafness.
• Ethnic groups with higher rates of consanguineous marriages (e.g., some Middle‑Eastern, South‑Asian, and North‑African populations) show a modestly higher incidence.
• Carriers of one pathogenic allele who are exposed to QT‑prolonging drugs (e.g., macrolide antibiotics, antipsychotics) may develop a milder phenotype, but they are not at risk for the full JLNS phenotype unless they inherit a second mutant allele.

Diagnosis

Diagnosing JLNS requires a combination of cardiac, audiologic, and genetic evaluation.

Electrocardiogram (ECG)

• Baseline 12‑lead ECG shows a **QTc (corrected QT) ≥ 480 ms** in most patients; some may exceed 500 ms.
• Holter monitoring or exercise stress testing can reveal “torsades de pointes” or other ventricular ectopy that may be intermittent.

Auditory testing

• Pure‑tone audiometry confirms bilateral sensorineural hearing loss.
• Otoacoustic emissions and auditory brainstem response (ABR) help differentiate congenital from acquired loss.

Genetic testing

• Next‑generation sequencing panels for inherited arrhythmia syndromes routinely include KCNQ1 and KCNJ5. Identification of biallelic pathogenic variants confirms JLNS.
• Testing of parents determines carrier status and informs family planning.

Additional investigations

• Serum electrolytes (especially potassium, magnesium, calcium) – low levels can exacerbate QT prolongation.
• Exercise treadmill test – patients with LQT1 typically have abnormal QT adaptation to exercise.
• Family cascade screening – ECG and genetic testing of siblings and extended relatives.

Diagnostic criteria (simplified)

According to the 2013 *American Heart Association*/ *American College of Cardiology* guidelines, JLNS is diagnosed when **all three** of the following are present:

1. Congenital sensorineural hearing loss.
2. QTc ≥ 480 ms on a resting ECG (or ≥ 460 ms with a confirmed pathogenic mutation).
3. Identified pathogenic homozygous or compound heterozygous mutation in KCNQ1 or KCNJ5.

Treatment Options

Because JLNS carries a high risk of life‑threatening arrhythmias, treatment is aggressive and lifelong.

Beta‑blockers (first‑line)

• Propranolol or nadolol** are preferred** because they have the longest half‑life and are non‑selective.
• Typical dose: propranolol 1–2 mg/kg/day divided every 6–8 hours; nadolol 1 mg/kg/day once daily.
• Beta‑blockers reduce sympathetic stimulation, which is a major trigger for arrhythmias in LQT1.

Implantable Cardioverter‑Defibrillator (ICD)

• Indicated for patients who survive cardiac arrest, have recurrent syncope despite beta‑blockade, or have a QTc > 500 ms with a strong family history of sudden death.
• Modern subcutaneous ICDs avoid trans‑venous leads, reducing infection risk in children.

Left Cardiac Sympathetic Denervation (LCSD)

• Surgical removal of the lower half of the left stellate ganglion.
• Considered when beta‑blockers are insufficient and an ICD is not feasible or as an adjunct to an ICD.
• Reduces arrhythmia triggers without affecting hearing.

Medication avoidance

• Strict avoidance of QT‑prolonging drugs (see CredibleMeds list).
• Avoid electrolyte‑depleting diuretics unless carefully monitored.

Hearing rehabilitation

• Early fitting of **cochlear implants** or **digital hearing aids** improves speech development.
• Regular audiology follow‑up is essential as hearing may change with age.

Lifestyle modifications

• Avoid competitive or high‑intensity sports that provoke rapid heart rates (e.g., sprinting, swimming races).
• Encourage moderate aerobic activity with physician clearance and continuous heart‑rate monitoring.
• Maintain optimal hydration and nutrition to prevent electrolyte disturbances.

Living with Jervell & Lange‑Nielsen Syndrome (Long QT Type 1)

While JLNS is serious, many patients lead active, fulfilling lives with appropriate management.

Daily management tips

• Medication adherence – take beta‑blockers exactly as prescribed; use a pill‑box or smartphone reminder.
• Regular follow‑up – at least every 6 months with a cardiologist experienced in channelopathies, plus annual audiology visits.
• Heart‑rate monitoring – many families use wearable devices (e.g., Apple Watch, Garmin) that can alert to sustained rates > 120 bpm during exercise.
• Emergency action plan – keep a written plan, include contact numbers, medication list, and instructions for by‑standers to call emergency services.
• Medical alert identification – wear a bracelet or necklace stating “Jervell & Lange‑Nielsen Syndrome – Long QT – Beta‑blocker” to inform first responders.
• Education at school – inform teachers, school nurses, and coaches about the condition, the need for medication at school, and activity restrictions.
• Family screening – test siblings and close relatives; carriers may need beta‑blockers if they exhibit a prolonged QT.

Psychosocial support

• Connect with patient advocacy groups such as the *Long QT Syndrome Foundation* or *Deaf Communities* for peer support.
• Consider counseling for anxiety related to sudden cardiac events, especially in adolescents.

Prevention

Because JLNS is genetic, primary prevention focuses on risk reduction for arrhythmic triggers and early detection in at‑risk families.

• Genetic counseling for couples who are known carriers.
• Prenatal testing (chorionic villus sampling or amniocentesis) can identify affected fetuses in families with a known mutation.
• Avoidance of QT‑prolonging substances – over‑the‑counter antihistamines, certain anti‑nausea drugs, and some anti‑depressants.
• Electrolyte management – maintain normal potassium (> 4.0 mmol/L) and magnesium (> 2.0 mg/dL) especially during illness or vomiting.
• Vaccination and infection control – febrile illnesses can raise heart rate and precipitate arrhythmia; prompt treatment of fever reduces risk.

Complications

If JLNS is not adequately treated, several serious complications can arise:

• Sudden cardiac death – the leading cause of mortality; risk greatest in untreated children < 5 years.
• Recurrent syncope – leading to injuries from falls.
• Heart failure – rare, but repeated arrhythmic episodes can impair ventricular function.
• Psychological impact – anxiety, depression, or social isolation due to activity restrictions.
• Medication side‑effects – excessive beta‑blockade can cause bradycardia, fatigue, or bronchospasm in asthmatic patients.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you notice any of the following:

• Sudden loss of consciousness or fainting, especially after exertion or a loud noise.
• Palpitations accompanied by dizziness, chest pain, or shortness of breath.
• Seizure‑like activity without a known seizure disorder.
• Sudden collapse while sleeping or during a nap (infant or child).
• Any sensation of “fluttering” in the chest that does not resolve within a minute.

If the person has an ICD, do not attempt to touch the device; instead, allow emergency responders to evaluate it.

---

References:

1. Mayo Clinic. “Long QT syndrome.” Accessed May 2024. https://www.mayoclinic.org
2. Cleveland Clinic. “Jervell and Lange‑Nielsen syndrome.” Accessed May 2024. https://my.clevelandclinic.org
3. American Heart Association / American College of Cardiology. 2013 Guideline for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation. 2013;128:e247‑e346.
4. World Health Organization. “Congenital hearing loss.” 2023. https://www.who.int
5. National Institutes of Health (NIH) Genetics Home Reference. “KCNQ1 gene.” Updated 2022. https://ghr.nlm.nih.gov
6. CredibleMeds. “List of QT‑prolonging drugs.” Updated 2024. https://www.crediblemeds.org

```